Literature DB >> 18416439

Sample size for equivalence trials: a case study from a vaccine lot consistency trial.

Jitendra Ganju1, Allen Izu, Alessandra Anemona.   

Abstract

For some trials, simple but subtle assumptions can have a profound impact on the size of the trial. A case in point is a vaccine lot consistency (or equivalence) trial. Standard sample size formulas used for designing lot consistency trials rely on only one component of variation, namely, the variation in antibody titers within lots. The other component, the variation in the means of titers between lots, is assumed to be equal to zero. In reality, some amount of variation between lots, however small, will be present even under the best manufacturing practices. Using data from a published lot consistency trial, we demonstrate that when the between-lot variation is only 0.5 per cent of the total variation, the increase in the sample size is nearly 300 per cent when compared with the size assuming that the lots are identical. The increase in the sample size is so pronounced that in order to maintain power one is led to consider a less stringent criterion for demonstration of lot consistency. The appropriate sample size formula that is a function of both components of variation is provided. We also discuss the increase in the sample size due to correlated comparisons arising from three pairs of lots as a function of the between-lot variance.

Mesh:

Substances:

Year:  2008        PMID: 18416439     DOI: 10.1002/sim.3273

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  2 in total

1.  Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine.

Authors:  Alain Luxembourg; Edson D Moreira; Rudiwilai Samakoses; Kyung-Hyo Kim; Xiao Sun; Roger Maansson; Erin Moeller; Susan Christiano; Joshua Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial.

Authors:  Yi-Juan Chen; Fan-Yue Meng; Qunying Mao; Jing-Xin Li; Hua Wang; Zheng-Lun Liang; Yun-Tao Zhang; Fan Gao; Qing-Hua Chen; Yuemei Hu; Zi-Jun Ge; Xin Yao; Hui-Jie Guo; Feng-Cai Zhu; Xiu-Ling Li
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.